 gut microbiota composition and levels of short chain fatty acids, SCFAs, and related metabolites are altered in Dutch and muscular dystrophy, DMD. These changes can be reversed by supplementation with sodium biturate, NAB, which has been shown to rescue muscle strength and autophagy, and reduce inflammation associated with excessive endocannabinoid signalling at CB1 receptors. This suggests that NAB could be used as a therapeutic agent for DMD. Additionally, this study found that NAB activates GPR109A and PAR receptors, which leads to reduced inflammation and increased autophagy in muscle cells. This research provides evidence that gut microbiota composition and SCF-based player role in DMD, and suggests that NAB could be used as a therapeutic agent for DMD. This article was authored by Hilal Kalkan, Esther Pogono, Deborah Parris, and others.